Sinopharm ToCell made a grand appearance at CBioPC 2020, demonstrating the strength of China's biopharmaceutical process support technology!

On the afternoon of November 21, the world-renowned 20th China Biologics Annual Conference (CBioPC 2020) came to a close at the Zhuhai International Convention and Exhibition Center. The event brought together more than 4,000 experts, scholars, entrepreneurs, research institutions, industry associations and corporate representatives in the field of biopharmaceuticals at home and abroad, and it was wonderful!

 

CBIOPC2020

Sinopharm ToCell brought a number of blockbuster products to the grand show, showcasing its cutting-edge products and process technology solutions in the fields of human vaccines, veterinary vaccines, antibody drugs, etc., and presenting its technological innovation achievements in the biopharmaceutical industry over the years. The Sinopharm ToCell booth attracted many guests and industry elites to stop and watch, and count the highlights of the Sinopharm ToCell booth with us.

 

Li Xiangrong, Vice President of China Biologic, and his delegation visited the ToCell booth

On the morning of November 20, Mr. Li Xiangrong, Vice President of Sinopharm Group China Biotechnology Co., Ltd., visited the Sinopharm ToCell booth and listened carefully to the report on ToCell’s innovative achievements in the field of biopharmaceuticals. He learned about the advantages and applications of personalized cell culture medium products, fully affirmed and highly praised ToCell’s product features and achievements, and hoped that ToCell could gain something from this display of new technologies and achievements in the biopharmaceutical industry, continue to create characteristics and highlights, and strive to become a supporter of China’s biopharmaceutical process technology!

Listen to the report on ToCell's innovative achievements

Learn about ToCell core products

Photo with ToCell Executive Vice President and Vice President

 

Feng Duojia, President of China Vaccine Industry Association, Shen Xinliang, scientist of China National Biotechnology Corporation, Li Xiuling, general manager of Shanghai Biological Products, Qi Fengchun of Jilin Wanfang Bioopik Biotechnology Co., Ltd., Fu Yongqi of Beijing Institute of Biological Products, China Many leaders, including Xu Honglin from the Institute of Biology, Dr. Guo Tong, President of Baoshihua Pharmaceutical Technology, and Gong Hengjian, Chairman of Lixiang.com, successively visited the ToCell booth of China Biopharmaceuticals for visit and guidance. They expressed their recognition of the product quality of ToCell and also expressed their appreciation for China Biopharmaceuticals’ We are full of confidence in future development.

Mr. Li Xiangrong and Ms. Li Xiuling guide ToCell work

Feng Duojia, President of China Vaccine Industry Association, Dr. Guo Tong, President of Gem Flower Pharmaceuticals, and Zhang Yu, Vice President of ToCell, took a group photo

 

 

Innovation drives development and science and technology serve health

Behind the impressive results, ToCell's high quality and pursuit of innovation are worth talking about in detail.

As the pioneer of the industrialization of personalized cell culture media in China, ToCell has developed a variety of personalized cell culture media based on years of research, development and technology application in the field of biopharmaceuticals. These include serum-free cell culture media, chemically defined cell culture media and low-serum cell culture media, which enhances China's independent and controllable capabilities in upstream raw materials of biopharmaceuticals and accelerates the development of the biopharmaceutical industry.

 

ToCell® Vero Cell Serum-Free and Animal Origin-Free Cell Culture Medium

It has the characteristics of fast cell proliferation rate, high clarity of harvest fluid, low host cell DNA, low host cell protein content, and low cell nuclear staining rate. It is suitable for serum-free cell adherent culture environment and meets the process requirements of large-scale industrial production in the fields of human rabies vaccine, veterinary rabies vaccine, IPV vaccine, EV71 vaccine, etc.

ToCell® Human Diploid Cell Low Serum Animal Origin-Free Cell Culture Medium

Lower serum addition amount, from 10% to 3%~5%; faster cell growth, higher expansion multiples, improved production efficiency; can directly replace conventional culture medium, human diploid cells have good morphology in low serum culture; reduce serum addition amount, reduce the risk of serum batch differences, and improve product quality. It is suitable for low serum cell culture environment and meets the production requirements of vaccines such as chickenpox, rabies, Japanese encephalitis, and hepatitis A.

ToCell® MDCK Serum-Free Animal Origin-Free Cell Culture Medium

It can complete the domestication and adaptation of MDCK cells more quickly, support the stable subculture and high-density suspension culture of MDCK cells in bioreactors, is serum-free and free of animal-derived components, significantly reduces downstream purification costs, is suitable for serum-free cell suspension culture environments, and meets the production process requirements of avian influenza and human seasonal influenza vaccines.

ToCell® MDCK Low Serum Adherent Cell Culture Medium

It supports high-density adherent culture of MDCK cells in fixed-bed bioreactors. When used with ToCell® MDCK VM virus maintenance medium, it can effectively increase viral titer, improve production efficiency, and reduce production costs. It is suitable for low-serum culture environments and meets the production process requirements of human seasonal influenza vaccines.

In addition, there are CHO, BHK21, HEK293, lnsect, Marc145, ST, PK15, MDBK and other cell culture media

 

Design for new products, seek refinement, service for sincerity

ToCell's technical and marketing teams have made sufficient preparations for CBioPC 2020. In addition to personalized cell culture media, we also brought high-quality bioreactors.

In recent years, Sinopharm ToCell has provided comprehensive process technology solutions based on bioreactor process design and manufacturing to many well-known Chinese biopharmaceutical companies, covering the entire process from process development, analytical method development and validation to large-scale commercial production to meet the rapidly developing dynamic needs of customers.

In 2019, ToCell participated in the construction of a vaccine production workshop, mainly responsible for the design and manufacture of bioreactors, and the supporting design, development, installation and commissioning of production line construction, including fully automatic CIP, SIP systems, liquid distribution systems, etc., and completed the vaccine production module consisting of bioreactors with working volumes ranging from 650L-4500L. After completion, it will become a domestic large-capacity, highly automated, and technologically advanced vaccine production workshop, completely replacing imports. The annual output value of this production line is expected to exceed 1 billion yuan.

ToCell Bio, a subsidiary of Sinopharm Group China National Biotec Group, is committed to providing reliable biopharmaceutical process support technologies for China's biopharmaceutical industry, enhancing China's independent and controllable capabilities in upstream biopharmaceutical raw materials and equipment, and accelerating the development of the biopharmaceutical industry.

Core Advantage Business

Personalized cell culture media

Independent design and manufacture of bioreactors

Biopharmaceutical process technology development

 

Contact Us

Tel：0512-63036292

Email：sales@txhbio.com

Web：www.txhbio.com

Add: 1F, Zhanhua Technology Building, No. 8 Pangyang Road, Wujiang District, Suzhou City, Jiangsu Province